Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Severe Alcoholic Hepatitis Clinical Trial

Official title:

Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03087968
• Other study ID #: HepQuant-002-2124
• Status: Withdrawn
• Phase: Early Phase 1
• Start date: July 31, 2016
• Est. completion date: September 13, 2017

Study information

• Verified date: September 2017
• Source: HepQuant, LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical investigation is a substudy within GS-US-416-2124, IND 129570, which is A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis. The use of the HepQuant SHUNT test is to assess liver disease severity before, during, and after treatment with GS-4997 or placebo, to assess liver disease severity.

Description:

The main study is a Phase 2, double blind, proof-of-concept, randomized study evaluating the safety, tolerability, and biological activity of GS-4997 in combination with prednisolone, compared to prednisolone alone, in subjects with severe, histologically-confirmed AH.

This substudy uses the HepQuant SHUNT Liver Diagnostic test to assess severity of disease at baseline and to track disease progression or improvement over the 24 weeks of the study. The HepQuant SHUNT test will be performed at baseline (Day 1) and at Weeks 1, 2, 4, 12, and 24 regardless of treatment Arm.

GS-4997 Dose and Mode of Administration. Subjects will be randomized 1:1 to either:

• Treatment Group A: GS-4997 18 mg (1 x 18 mg tablet) AND prednisolone 40 mg (4 x 10 mg tablets), both administered orally once daily

• Treatment Group B: GS-4997 placebo (1 tablet) AND prednisolone 40 mg (4 x 10 mg tablets), both administered orally once daily

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 13, 2017
• Est. primary completion date: September 13, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Willing and able to give informed consent prior to any study specific procedures being performed. In individuals with hepatic encephalopathy (HE) which may impair decision-making, consent will be obtained per hospital procedures (eg, by Legally Authorized Representative)

2. Clinical diagnosis of severe AH

3. Maddrey's DF = 32 at screening

Exclusion Criteria:

Key Exclusion Criteria:

1. Pregnant or lactating females;

2. Other causes of liver disease including chronic hepatitis B (hepatitis B surface antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen hepatotoxicity, biliary obstruction, and autoimmune liver disease;

3. Serum AST >400 U/L or ALT >300 U/L;

4. MELD >30 at screening;

5. Maddrey's DF >60 at screening;

6. Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria;

7. Concomitant or previous history of hepatocellular carcinoma;

8. History of liver transplantation;

9. HIV Ab positive;

10. Clinical suspicion of pneumonia;

11. Uncontrolled sepsis;

12. Uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of screening that was associated with shock or required transfusion of more than 3 units of blood;

13. Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine >221 µmol/L (>2.5 mg/dL) or the requirement for renal replacement therapy;

14. Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory support (ie, endotracheal intubation or positive-pressure ventilation);

15. Portal vein thrombosis;

16. Acute pancreatitis;

17. Cessation of alcohol consumption for more than 2 months before Baseline/ Day 1 NOTE:

Other protocol defined Inclusion/ Exclusion criteria may apply.

Related Conditions & MeSH terms

• Hepatitis, Alcoholic
• Liver Diseases
• Severe Alcoholic Hepatitis

Intervention

Drug:
• GS-4997
Experimental drug
• Prednisolone
Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.

Device:
• HepQuant SHUNT Test
The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease. For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples.

Drug:
• Placebo
Placebo

Locations

Country	Name	City	State
United States	Emory University	Atlanta	Georgia
United States	Southern California Research Center	Coronado	California
United States	The Liver Institute at Methodist Dallas Medical Center	Dallas	Texas
United States	University of Mississippi Medical Center	Jackson	Mississippi
United States	University of Miami	Miami	Florida
United States	University of Minnesota	Minneapolis	Minnesota
United States	Intermountain Medical Center	Murray	Utah
United States	Liver Institute of Virginia	Newport News	Virginia
United States	University of Pennsylvania	Philadelphia	Pennsylvania
United States	Liver Institute of Virginia	Richmond	Virginia
United States	VCU Health System	Richmond	Virginia
United States	American Research Corporation at the Texas Liver Institute	San Antonio	Texas
United States	University of Washington	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
HepQuant, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To compare the change in (DSI ) Disease Severity Index between GS-4997 treatment and placebo arms	Using the SHUNT DSI to evaluate the liver, this outcome will compare the two arms to determine if SHUNT DSI is able to measure a change between the experimental and control groups.	HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24
Secondary	Secondary Outcome 1	To determine the relationship of baseline Disease Severity Index (DSI) to mortality risk;	HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24
Secondary	Secondary Outcome 2	To determine the relationship of change in Disease Severity Index (DSI) to mortality risk	HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24
Secondary	Secondary Outcome 3	To correlate baseline Disease Severity Index (DSI) with baseline Maddrey, MELD, and Lille scorestest with the pharmacokinetics of GS-4997	HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24
Secondary	Secondary Outcome 4	To determine the relationship between baseline Disease Severity Index (DSI), Maddrey, MELD, and Lille scores and mortality	HepQuant Shunt testing will be done at baseline (Day1), Week 1, Week 4, Week 12, Week 24